BDB001 (EIK1001)

DRUG2 trials

Sponsors

Eikon Therapeutics

Conditions

Tumor, Solid

Phase 1

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

CompletedNCT03486301

Eikon TherapeuticsTumor, Solid

Start: 2018-02-15End: 2024-04-30Updated: 2025-11-12

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

CompletedNCT04196530

Eikon TherapeuticsTumor, Solid

Start: 2019-11-21End: 2024-08-15Updated: 2025-11-12

Related Papers

Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.

Journal of Clinical Oncology2024-06-013 citations

Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.

Journal of Clinical Oncology2024-06-01

Abstract 7172: Pharmacokinetic/biomarker (PK/BMx) analysis of the toll-like receptor 7 and 8 (TLR7/8) agonist EIK1001 in phase 1 studies in participants (Pts) with solid tumors

Cancer Research2024-03-22

472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-011 citations

BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.

Journal of Clinical Oncology2021-05-2012 citations

324 BDB001, a Toll-Like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors

Regular and Young Investigator Award Abstracts2020-11-011 citations